Medtronic plc (MDT) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Medtronic's earnings call reveals strong revenue growth, positive product developments, and optimistic guidance. The increase in full-year revenue growth guidance to 5.5% and the raised EPS guidance reflect confidence in future performance. The Q&A section supports this with plans for accelerated growth in key areas and high single-digit EPS growth. Despite some management vagueness, the overall sentiment is positive, with strong growth in the MedSurg and Diabetes businesses and strategic investments. The lack of market cap information limits the prediction accuracy, but the strong fundamentals suggest a positive stock price movement.
Key Financial Performance
Organic Revenue Growth 6% organic revenue growth, marking the highest revenue growth in 10 quarters. This growth is attributed to strong end markets and new innovative technologies.
Cardiac Ablation Solutions (CAS) Business 80% year-over-year growth, with PFA growing nearly 200% worldwide. The growth is driven by high physician demand for Sphere-9 catheter and increased installed base, which is a leading indicator for future revenue growth and margin expansion.
Cardiovascular Portfolio 11% year-over-year revenue growth, with 13% growth in the U.S. This is the strongest growth in 10 years, excluding COVID comparisons. CAS contributed significantly to this growth.
Cardiac Rhythm Management (CRM) 5% growth, driven by double-digit growth in Micra, mid-teens growth in 3830 CSP lead, and over 70% growth in Aurora EV-ICD.
Peripheral Vascular Health High single-digit growth, driven by broad strength across the endoVenous portfolio.
Structural Heart Low single-digit growth, with stronger performance internationally and share gains in Europe. U.S. growth was offset by annualized Evolut FX+ launch and competitive pressure.
Neuroscience Portfolio 3% growth, slightly below expectations. Growth is expected to improve in the fourth quarter due to new product launches like Stealth AXiS.
Cranial & Spinal Technologies (CST) Mid-single-digit growth, including 8% growth from Core Spine. Growth is supported by the new Stealth AXiS navigation and robotics platform.
Specialty Therapies Flat results, with expected improvement in coming quarters due to new product developments.
Neuromodulation 4% growth, driven by the rollout of Inceptiv SCS and BrainSense aBDS technologies.
MedSurg Portfolio 3% growth, led by 10% growth in Endoscopy and 7% growth in Acute Care & Monitoring. Surgical business grew by 1%, with strength in energy, wound management, and hernia.
Diabetes Business (MiniMed) 15% reported growth and over 8% organic growth, driven by strong international performance and new product launches like Simplera Sync and Instinct.
Revenue $9 billion, representing 8.7% reported growth and 6% organic growth. U.S. growth was 6%, the strongest since fiscal year 2019, excluding COVID comparisons.
Adjusted Gross Margin 64.9%, ahead of expectations. Mix was negatively impacted by CAS and Diabetes, but pricing, FX, and cost efficiency programs provided benefits.
Adjusted Operating Profit $2.2 billion, resulting in an adjusted operating margin of 24.1%, ahead of expectations.
Adjusted EPS $1.36, $0.03 above the midpoint of the guidance range.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PFA platform for AFib: Achieved nearly 200% worldwide growth, gaining 4 points of share in a $13 billion market. Sphere-9 catheter is versatile and efficient, with plans to expand indications and geographies.
Symplicity Spyral for hypertension: Provides a one-time, minimally invasive treatment for hypertension. Strong patient outcomes and growing clinical data. Direct-to-consumer campaign increased website visits 50x.
Altaviva for urinary incontinence: A small, long-lasting device with early positive feedback. Focused on training and consumer activation.
Hugo surgical robot: Received FDA clearance for urologic procedures. Initial installations and cases completed, with plans to expand indications.
Stealth AXiS Surgical System: FDA-cleared for spinal procedures, integrating AI-powered planning, robotics, and navigation. Plans to expand into cranial and ENT indications.
Cardiac Ablation Solutions (CAS): Achieved 80% year-over-year growth, doubling the growth rate of competitors. Plans to double revenue to $2 billion by FY27.
Hypertension treatment market: Building a new market with Symplicity Spyral, targeting 18 million U.S. patients with uncontrolled hypertension.
Urinary incontinence market: Scaling Altaviva device, targeting 16 million U.S. patients.
Surgical robotics market: Hugo robot launched in the U.S., with plans to expand indications and leverage AI-powered ecosystem.
Revenue growth: Achieved 6% organic revenue growth, the highest in 10 quarters.
Geographic performance: High single-digit growth in Western Europe and mid-single-digit growth in the U.S. and Japan.
Adjusted gross margin: 64.9%, ahead of expectations, with pricing and FX benefits offsetting mix challenges.
Adjusted EPS: $1.36, exceeding guidance by $0.03.
M&A and investments: Acquired CathWorks and invested in Anteris to enhance digital and ecosystem capabilities.
Pipeline innovation: Focused on advancing technologies in areas like spine surgery, cardiac rhythm management, and neurovascular treatments.
Market-building campaigns: Launched direct-to-consumer campaigns for Symplicity Spyral and Altaviva to drive patient engagement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Compliance Risks: The company faces ongoing regulatory hurdles, including FDA clearances and CE Mark approvals for new products like Sphere-360 and Stealth AXiS. Delays or failures in obtaining these approvals could impact product launches and revenue growth.
Market Adoption Challenges: Building new markets for products like Symplicity Spyral for hypertension and Altaviva for urinary incontinence takes time and requires significant investment in consumer education and physician training. Slow adoption could delay revenue realization.
Competitive Pressures: The Structural Heart segment experienced competitive pressure in the U.S., which partially offset international growth. This indicates a challenging competitive landscape that could impact market share.
Supply Chain and Manufacturing Risks: The Diabetes business is currently impacted by early manufacturing ramp-up challenges for new products like Simplera, which affects gross margins. Additionally, tariffs have a significant financial impact, amounting to $93 million this quarter.
Economic and Geopolitical Risks: The company faces ongoing volume-based procurement (VBP) challenges in China, which have impacted growth in the Neurovascular segment. Broader economic uncertainties could exacerbate these issues.
Product Performance and Safety Risks: The recall of the Vantage product in the Neurovascular segment has posed challenges, although it is mostly resolved. Any future recalls or safety issues could harm the company's reputation and financial performance.
Strategic Execution Risks: The company is managing multiple large-scale product launches and market expansions simultaneously, such as Hugo in the U.S. and Sphere-360 in Europe. Poor execution in any of these areas could dilute focus and impact overall performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Fiscal '26 organic revenue growth guidance is approximately 5.5%. Fourth quarter revenue growth is expected to be around 6%, consistent with Q3.
Gross Margin: Fiscal '26 gross margin is expected to increase slightly excluding tariffs. Including tariffs, gross margin is expected to decrease by roughly 30 basis points.
Operating Profit: Fiscal '26 adjusted operating profit is expected to grow approximately 5% or 7% excluding tariffs. Fiscal '26 operating margin is expected to be roughly flat excluding tariffs, and down about 50 basis points including the tariff impact.
Earnings Per Share (EPS): Fiscal '26 EPS guidance is maintained in the range of $5.62 to $5.66. High single-digit EPS growth is expected in fiscal year '27.
Product Launches and Market Expansion: Sphere-9 catheter is planned for launch in Japan and expanded indication submission in VT in the first half of calendar '26. Sphere-360 catheter commercialization in Europe is expected this spring, with U.S. launch following. Symplicity Spyral for hypertension and Altaviva for urinary incontinence are in early stages of market building, with long-term growth potential. Hugo surgical robot has begun U.S. launch, with plans to expand into additional indications like hernia.
Innovation and Pipeline: Stealth AXiS Surgical System for spinal procedures is expected to contribute to growth starting in Q4. MiniMed Fit patch pump is on track for U.S. FDA submission by fall '26. Multiple new product developments in Neuroscience and other segments are expected to drive growth in the coming quarters.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the plans for accelerating revenue growth and high single-digit EPS growth for FY '27?
A:The company plans to continue strong growth in CAS, Symplicity for hypertension, and Altaviva for overactive bladder. CST with Stealth AXiS and Neurovascular with new products like Onyx indication for MMAe and Neuroguard are expected to contribute. Gross margin improvements are anticipated due to CAS mix effects and the Diabetes separation. The company also plans to invest in R&D and M&A. High single-digit EPS growth guidance for FY '27 is reiterated.
Q:Is the growth acceleration excluding the extra selling week in FY '27?
A:The extra selling week will be part of the growth acceleration. However, the company expects growth acceleration even excluding the extra week.
Q:What are the goalposts for tracking the progress of RDN and Altaviva launches?
A:The company is seeing strong leading indicators such as training 500+ physicians for Altaviva and opening 200+ new accounts for RDN. They are also tracking covered lives for RDN, which is up to 100 million in the U.S. More concrete goalposts will be laid out as the launches mature.
Q:How is the company thinking about CAS growth and the EP market?
A:The EP market is expected to grow at least high teens in FY '27. CAS growth is expected to sustain in Q4, and the company believes it is well-positioned with its portfolio of catheters and mapping solutions. The Sphere-9 catheter is versatile and gaining traction.
Q:What is the approach to capital allocation and M&A?
A:The company is focused on tuck-in M&A deals, which can be up to several billion dollars, and venture investments tied to strategy. They prioritize high-growth areas and may have multiple investments in key markets, as seen with Pulsed Field Ablation.
Q:What are the high-level drivers for achieving high single-digit EPS growth in FY '27?
A:Drivers include accelerated revenue growth, gross margin improvements from CAS mix and Diabetes separation, leverage on SG&A, and investments in R&D and sales/marketing. Temporary dilution from Diabetes separation and M&A is expected but factored into the guidance.
Q:Why did the company invest in Anteris instead of acquiring it?
A:The investment in Anteris is seen as an opportunity to expand in the Structural Heart space, particularly in the balloon-expandable TAVR market. The company may pursue multiple investments in this area.
Q:When will CAS gross margin dilution from capital equipment sales normalize?
A:The mix is expected to improve in the second half of FY '27 as catheter sales increase. CAS is expected to drive gross margin improvement starting in FY '27.
Q:What is the timeline for Hugo to significantly impact the Surgical business?
A:Hugo is expected to see a step-up in Q4 with strong procedure growth and utilization globally. However, it may take time to significantly impact the $6 billion Surgical business.
Q:What goes into developing the renal denervation market?
A:Market development involves building referral pathways, hiring market development staff, and focusing on health economics, coding, and billing. The company is also investing in direct-to-consumer marketing and building the Symplicity brand.
Q:What is the significance of the Stealth AXiS platform?
A:Stealth AXiS is a new robotic platform that integrates seamlessly into the existing navigation workflow, which is used in 70% of U.S. procedures. It offers enhanced functionality and is expected to grow the market and extend the company's lead in spine surgery robotics.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on the exact growth contribution of the extra selling week in FY '27 and the detailed timeline for Hugo to significantly impact the Surgical business. Additionally, they did not provide concrete goalposts for RDN and Altaviva launches, stating that these would be laid out as the launches mature.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACM tax
Altaviva incontinence
CAS PFA
COGS
CRDN
CRM ACM
CST
China digit
Clinic
Endoscopy
FDA clearance
Hugo robot
Neuroguard
Neurovascular
Touch Surgery
VBP
Vascular Health
carotid stent
category
comp
contributor
engine
financials
hypertension Altaviva
indication system
installation case
interest
margin expectation
market Medtronic
navigation
physician patient
point tariff
portfolio expectation
reason
release system
remainder
safety durability
spine
tariff margin
tax pressure
teen
venture
versatility
workflow
MDT Transcript
Medtronic plc (MDT) Q4 2026 Earnings Call Transcript
Unknown6-3
The earnings call summary lacks detailed information on key aspects such as operational updates, strategic initiatives, and risks, which limits the analysis. The financial section provides only a limited view of revenue comparisons. Without additional insights from the Q&A, the sentiment remains neutral. This lack of comprehensive data suggests no significant short-term stock price movement, resulting in a neutral prediction.
Medtronic plc (MDT) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-11
Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Medtronic plc (MDT) Q3 2026 Earnings Call Transcript
Positive2-17
Medtronic's earnings call reveals strong revenue growth, positive product developments, and optimistic guidance. The increase in full-year revenue growth guidance to 5.5% and the raised EPS guidance reflect confidence in future performance. The Q&A section supports this with plans for accelerated growth in key areas and high single-digit EPS growth. Despite some management vagueness, the overall sentiment is positive, with strong growth in the MedSurg and Diabetes businesses and strategic investments. The lack of market cap information limits the prediction accuracy, but the strong fundamentals suggest a positive stock price movement.
MDT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
